We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01074918
Recruitment Status : Completed
First Posted : February 24, 2010
Last Update Posted : December 11, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
The goal of this study is to compare the effects of Potassium Magnesium Citrate to Potassium Chloride on blood pressure among patients with pre-hypertension or mild hypertension. We will also test whether Potassium Magnesium Citrate increases excretion of large amounts of sodium in the urine.

Condition or disease Intervention/treatment Phase
Pre-hypertension Hypertension Drug: Potassium, Magnesium, Citrate Drug: Potassium Chloride Phase 1 Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Supportive Care
Official Title: Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients; Role of Natriuresis
Study Start Date : September 2009
Primary Completion Date : September 2012
Study Completion Date : December 2012

Arms and Interventions

Arm Intervention/treatment
Experimental: Potassium Magnesium Citrate Drug: Potassium, Magnesium, Citrate
Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.
Active Comparator: Potassium Chloride Drug: Potassium Chloride
Potassium Chloride

Outcome Measures

Primary Outcome Measures :
  1. Blood Pressure [ Time Frame: 8 weeks ]
    We have estimated to detect a 4 mmHg difference, with a standard deviation estimated at 8 mmHg.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age greater than 21 years
  • BMI > 18.5 kg/m2 and < 40 kg/m2
  • Prehypertension and mild hypertension: BP systolic 120-159 mmHg, diastolic 80-95 mmHg
  • Must agree to limit lifestyle changes including: 1) embarking on a new exercise or weight reduction program 2) altering alcohol intake during the trial.

Exclusion Criteria:

  • Taking blood pressure lowering medication
  • Diabetes mellitus
  • Renal disease
  • Active cardiac disease
  • Active liver disease
  • Chronic diarrhea
  • Chronic NSAID use
  • Active or suspected drug use
  • Uncontrolled psychiatric disease
  • HIV infection
  • Missed more than 20% of clinic visits in the last yr
  • Prescription of diuretics for any reason
  • A patient taking nutritional supplements including multivitamins that is unwilling to discontinue them,\
  • Consumption of greater than 14 alcoholic beverages per week
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01074918

United States, Texas
Dallas VA Medical Center
Dallas, Texas, United States, 75216
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Sponsors and Collaborators
University of Texas Southwestern Medical Center
More Information

Responsible Party: Orson Moe, Professor of Internal Medicine, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT01074918     History of Changes
Other Study ID Numbers: 012007-080
First Posted: February 24, 2010    Key Record Dates
Last Update Posted: December 11, 2013
Last Verified: December 2013

Keywords provided by Orson Moe, University of Texas Southwestern Medical Center:

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Citric Acid
Magnesium citrate
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents